Physician profile
Samar Aslam
NPI 1518306612
$646.73
in general payments reported to CMS, 2019-2025
15 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $65.74 · 2021: $158 · 2022: $19.14 · 2023: $16.33 · 2024: $138 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $192.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $83.12 | 2021-2024 | |
| Lilly USA, LLC | $80.18 | 2019-2021 | |
| Sanofi Pasteur INC. | $53.46 | 2019-2021 | |
| Exact Sciences Corporation | $34.75 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $33.84 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $25.95 | 2019 | |
| Corium, LLC | $23.97 | 2025 | Azstarys |
| Pfizer INC. | $23.21 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2024 | Jardiance |
| Almatica Pharma LLC | $17.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.33 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $14.60 | 2021 | |
| Tris Pharma INC | $14.23 | 2024 | Dyanavel Xr |
| Neos Therapeutics, Lp | $13.33 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.